Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Par's Megace ES Clears FDA; Company Will Target Generic Megestrol Users

This article was originally published in The Pink Sheet Daily

Executive Summary

Concentrated version of the appetite stimulant megestrol acetate oral suspension will launch the week of July 11 through Par's 59-rep sales force. The company expects to convert half the $60 mil. generic market for megestrol acetate oral suspension to Megace ES by the end of 2006.

You may also be interested in...



Par Adds To HIV Portfolio With Immtech’s Pafuramidine

Par is projecting a late 2007 or early 2008 NDA submission for pneumocystis pneumonia in AIDS, the firm tells “The Pink Sheet” DAILY.

Par Adds To HIV Portfolio With Immtech’s Pafuramidine

Par is projecting a late 2007 or early 2008 NDA submission for pneumocystis pneumonia in AIDS, the firm tells “The Pink Sheet” DAILY.

Par Will Restate FY 2004, 2005 Results Due to Accounting Error

The restatement could lower actual revenues by $55 mil. over the period.

Related Content

Topics

UsernamePublicRestriction

Register

LL1135424

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel